Teclistamab BCMA × CD3 bispecific monotherapy — continuous SC weekly (post step-up)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-TECLISTAMAB |
|---|
| ID | REGIMEN-TECLISTAMAB-MONO-MM |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-01 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-MAJESTEC-1-MOREAU-2022 SRC-NCCN-MM-2025 |
Notes
Weekly continuous monotherapy phase of teclistamab — separated from step-up phase (REGIMEN-TECLISTAMAB-STEP-UP-DOSING-MM) to make inpatient/outpatient transition explicit. MajesTEC-1 (Moreau 2022, ASH 2023 update): triple-class refractory MM after ≥3 prior lines (median 5) — ORR 63%, CR/sCR 39%, mPFS ~11 mo, mDOR ~22 mo. FDA approved 4L+ triple-class refractory (post-PI, post-IMiD, post-anti-CD38). Q2-weekly dosing per protocol amendment for patients sustaining ≥VGPR ≥6 mo.
Used By
No reverse references found in the YAML corpus.